Ramelteon-induced nightmares: a case report
Shah C, Kablinger A
Published in Asian Journal of Psychiatry
Methodology
Single-patient case report describing onset of nightmares after starting ramelteon for insomnia disorder and their resolution on discontinuation, with a literature search for prior reports.
Key Findings
A single patient prescribed ramelteon, the only FDA-approved melatonin receptor agonist for insomnia, developed vivid nightmares shortly after starting the drug. The nightmares resolved after ramelteon was discontinued. The authors found no previously documented cases of ramelteon-induced nightmares in the literature and note that its effects on REM sleep, when dreaming occurs, need further study.
Conclusions
Shortly after initiation of ramelteon, he described vivid nightmares leading to discontinuation of ramelteon. The nightmares ameliorated with ramelteon discontinuation.
Limitations
A single case report with no control or rechallenge, so cause and effect cannot be established; the finding is a signal for further study rather than evidence of a real risk.
Supplements Studied
Shortly after initiation of ramelteon, he described vivid nightmares leading to discontinuation of ramelteon. The nightmares ameliorated with ramelteon discontinuation.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.